© The Author 2007. Published by Oxford University Press.
ARTICLES |
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer
On behalf of the European Organisation for Research and Treatment of Cancer-Lung Cancer Group
Affiliations of authors: Department of Respiratory Medicine, University Hospital Ghent, Gent, Belgium (JPVM); Department of Radiation Therapy, Arnhem Radiotherapeutic Institute, Arnhem, The Netherlands (GWPMK); Departments of Respiratory Medicine and Thoracic Surgery, University Hospital Antwerp, Antwerp, Belgium (JPVM, PEYVS); European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium (CL, CD); Departments of Pulmonology and Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands (EFS, GG); Department of Pulmonology, Sint Antonius Ziekenhuis, Nieuwegein, The Netherlands (FS); Department of Medical Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands (VCTH); Department of Pulmonology, Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch, The Netherlands (BB); Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands (NvZ); Departments of Pulmonology and Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands (JPVM, TAWS)
Correspondence to: Jan P. van Meerbeeck, MD, PhD, Department of Respiratory Medicine, 7K12IE, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium (e-mail: jan.vanmeerbeeck{at}ugent.be).
Background: Induction chemotherapy before surgical resection increases survival compared with surgical resection alone in patients with stage IIIA-N2 non–small-cell lung cancer (NSCLC). We hypothesized that, following a response to induction chemotherapy, surgical resection would be superior to thoracic radiotherapy as locoregional therapy.
Methods: Selected patients with histologic or cytologic proven stage IIIA-N2 NSCLC were given three cycles of platinum-based induction chemotherapy. Responding patients were subsequently randomly assigned to surgical resection or radiotherapy. Survival curves were estimated using Kaplan–Meier analyses from time of randomization.
Results: Induction chemotherapy resulted in a response rate of 61% (95% confidence interval [CI] = 57% to 65%) among the 579 eligible patients. A total of 167 patients were allocated to resection and 165 to radiotherapy. Of the 154 (92%) patients who underwent surgery, 14% had an exploratory thoracotomy, 50% a radical resection, 42% a pathologic downstaging, and 5% a pathologic complete response; 4% died after surgery. Postoperative radiotherapy was administered to 62 (40%) of patients in the surgery arm. Among the 154 (93%) irradiated patients, overall compliance to the radiotherapy prescription was 55%, and grade 3/4 acute and late esophageal and pulmonary toxic effects occurred in 4% and 7%; one patient died of radiation pneumonitis. Median and 5-year overall survival for patients randomly assigned to resection versus radiotherapy were 16.4 versus 17.5 months and 15.7% versus 14%, respectively (hazard ratio = 1.06, 95% CI = 0.84 to 1.35). Rates of progression-free survival were also similar in both groups.
Conclusion: In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiotherapy. In view of its low morbidity and mortality, radiotherapy should be considered the preferred locoregional treatment for these patients.
| CONTEXT AND CAVEATS Prior knowledge Compared with surgery alone, induction chemotherapy before surgery improves survival of patients with stage IIIA NSCLC. Study design A randomized controlled trial of surgery versus thoracic radiotherapy in patients with stage IIIA-N2 NSCLC who responded to induction chemotherapy. Contributions Median survival time and 5-year overall survival rates for patients who underwent surgery were 16.4 months and 15.7%; those for patients who underwent radiotherapy were 17.5 months and 14%. Implications In patients with stage IIIA-N2 NSCLC who respond to induction chemotherapy, subsequent surgery did not improve overall or progression-free survival compared with radiation therapy. Radiotherapy may be the preferred treatment for these patients, given its low morbidity and mortality. Limitations Patient selection may have been affected by changing standards for tumor staging during trial accrual. Outcome may have been affected by changing treatment standards during the trial.
|
Gijs W. P. M. Kramer is deceased.
Manuscript received July 31, 2006; revised January 8, 2007; accepted January 29, 2007.
Correspondence about this Article
Editorial about this Article
Related Articles in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1210.
J Natl Cancer Inst 2007 99: 415-418.
J Natl Cancer Inst 2007 99: 413.
J Natl Cancer Inst 2007 99: 413.
This article has been cited by other articles:
|
|
 |
|
  Y. Shimada, M. Tsuboi, H. Saji, K. Miyajima, J. Usuda, O. Uchida, N. Kajiwara, T. Ohira, T. Hirano, H. Kato, et al. The prognostic impact of main bronchial lymph node involvement in non-small cell lung carcinoma: suggestions for a modification of the staging system. Ann. Thorac. Surg., November 1, 2009; 88(5): 1583 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kappers, J. W. van Sandick, J. A. Burgers, J. S.A. Belderbos, M. W. Wouters, N. van Zandwijk, and H. M. Klomp Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 741 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. Ratto, R. Costa, P. Maineri, A. Alloisio, P. Bruzzi, and B. Dozin Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection? J. Thorac. Cardiovasc. Surg., October 1, 2009; 138(4): 849 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Thomas Stage IIIA N2 non-small-cell lung cancer: current controversies in combined-modality therapy Eur. J. Cardiothorac. Surg., September 1, 2009; 36(3): 431 - 432. [Full Text] [PDF]
|
|
|
|
|
|
H. Decaluwe, P. De Leyn, J. Vansteenkiste, C. Dooms, D. Van Raemdonck, P. Nafteux, W. Coosemans, and T. Lerut Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival Eur. J. Cardiothorac. Surg., September 1, 2009; 36(3): 433 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Brunelli, A. Charloux, C. T. Bolliger, G. Rocco, J-P. Sculier, G. Varela, M. Licker, M. K. Ferguson, C. Faivre-Finn, R. M. Huber, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Eur. Respir. J., July 1, 2009; 34(1): 17 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Steger, T. Walles, B. Kosan, T. Walker, T. Kyriss, S. Veit, J. Dippon, and G. Friedel Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival. Ann. Thorac. Surg., June 1, 2009; 87(6): 1676 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Stoelben and C. Ludwig Chest wall resection for lung cancer: indications and techniques Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 450 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Rice, S. Swisher, K. Pisters, F. Fossella, R. Herbst, W. Hofstetter, M. Kies, R. Komaki, S. Lippman, R. Mehran, et al. Comment on "Treatment of Non-small Cell Lung Cancer Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)" Chest, December 1, 2008; 134(6): 1349 - 1349. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr., and C. W. Stevens Response Chest, December 1, 2008; 134(6): 1350 - 1350. [Full Text] [PDF]
|
|
|
|
|
|
C. H. Kang, Y. J. Ra, Y. T. Kim, S.-H. Jheon, S.-w. Sung, and J. H. Kim The Impact of Multiple Metastatic Nodal Stations on Survival in Patients With Resectable N1 and N2 Nonsmall-Cell Lung Cancer Ann. Thorac. Surg., October 1, 2008; 86(4): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. I. Pass Lung Cancer Staging Techniques and Induction Therapy: Maybe Timing Is Everything J. Clin. Oncol., July 10, 2008; 26(20): 3306 - 3307. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. van Meerbeeck, S. Meersschout, R. De Pauw, I. Madani, and W. De Neve Modern Radiotherapy as Part of Combined Modality Treatment in Locally Advanced Non-Small Cell Lung Cancer: Present Status and Future Prospects Oncologist, June 1, 2008; 13(6): 700 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Van Schil Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 718 - 718. [Full Text] [PDF]
|
|
|
|
|
|
P. Garrido, J. L. Gonzalez-Larriba, A. Insa, M. Provencio, A. Torres, D. Isla, J. M. Sanchez, F. Cardenal, M. Domine, J. R. Barcelo, et al. Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non Small-Cell Lung Cancer Patients: The Spanish Lung Cancer Group Trial 9901 J. Clin. Oncol., October 20, 2007; 25(30): 4736 - 4742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Leo, T. De Pas, G. Catalano, G. Piperno, G. Curigliano, P. Solli, G. Veronesi, F. Petrella, and L. Spaggiari Re: Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non Small-Cell Lung Cancer J Natl Cancer Inst, August 1, 2007; 99(15): 1210 - 1210. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Johnson, V. W. Rusch, and A. T. Turrisi Scalpels, Beams, Drugs, and Dreams: Challenges of Stage IIIA-N2 Non-Small-Cell Lung Cancer J Natl Cancer Inst, March 21, 2007; 99(6): 415 - 418. [Full Text] [PDF]
|
|